Rapid Micro Biosystems Posts Record 2025 Results, Guides Higher

Rapid Micro Biosystems ( (RPID) ) has issued an announcement.

On March 12, 2026, Rapid Micro Biosystems reported record results for the fourth quarter and full year 2025, with Q4 revenue rising 37% year over year to $11.3 million and full-year revenue up 20% to $33.6 million, driven by increased product and recurring revenue despite a wider quarterly net loss of $12.5 million. The company highlighted strong commercial momentum, including a record multi-system Growth Direct order from Amgen in late 2025 and a meaningful multi-system order from Samsung Biologics in early 2026, and guided 2026 revenue to $37–$41 million with improved gross margins and 30–38 system placements, underscoring growing global adoption of its platform even as it continues to operate at a loss.

For 2025, Rapid Micro Biosystems placed 28 Growth Direct systems and achieved modest positive gross margin for the year, aided by tighter operating expenses but offset by inventory write-offs that pressured margins in the fourth quarter. The company ended 2025 with approximately $39 million in cash and $25 million of undrawn debt capacity, providing liquidity to fund its strategy of expanding system placements, enhancing gross margins, and advancing new product innovation while large biopharmaceutical customers standardize on its automation technology.

The most recent analyst rating on (RPID) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Rapid Micro Biosystems stock, see the RPID Stock Forecast page.

Spark’s Take on RPID Stock

According to Spark, TipRanks’ AI Analyst, RPID is a Neutral.

The score is held back primarily by weak financial fundamentals (continued large losses and negative operating cash flow) and an unattractive earnings-based valuation (negative P/E). These are partially offset by strong technical momentum and a generally positive earnings call featuring raised revenue guidance and notable customer/order traction.

To see Spark’s full report on RPID stock, click here.

More about Rapid Micro Biosystems

Rapid Micro Biosystems, Inc. is a life sciences technology company that provides mission-critical automation solutions to support efficient manufacturing and rapid, safe release of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes microbial quality control testing in large, complex pharmaceutical manufacturing operations worldwide, bringing quality control closer to the manufacturing floor to improve speed, accuracy, compliance, and operational efficiency.

Average Trading Volume: 239,219

Technical Sentiment Signal: Strong Buy

Current Market Cap: $194.1M

For a thorough assessment of RPID stock, go to TipRanks’ Stock Analysis page.